Medications Development for the Treatment of Amphetamine and Amphetamine-Like Related Disorders (R01)

The summary for the Medications Development for the Treatment of Amphetamine and Amphetamine-Like Related Disorders (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Medications Development for the Treatment of Amphetamine and Amphetamine-Like Related Disorders (R01): Purpose. The goal of this program announcement is to encourage preclinical and clinical research directed towards the identification, evaluation and development of safe and effective medications for the treatment of Amphetamine and Amphetamine-like Related Disorders (ARDs), most importantly methamphetamine abuse and methamphetamine dependence. According to the DSM-IV-TR, the class of amphetamine and amphetamine-like substances includes all substances with a substituted-phenylethylamine structure, such as amphetamine, dextroamphetamine, methamphetamine, and MDMA (3,4-methylenedioxymethamphetamine). Also included are those substances that are structurally different but have amphetamine-like action, such as methylphenidate, some agents used as appetite suppressants, and khat. Amphetamines, amphetamine-like substances and methamphetamine especially, are highly addictive central nervous system stimulants that can be injected, snorted, smoked, or ingested orally. Of all the ARDs, prevalence data is most readily available for methamphetamine abuse and dependence. This data indicates that methamphetamine use continues to be a major public health concern in the United States for all segments of the population. Methamphetamine is unique in that it can be easily manufactured in clandestine laboratories using store-bought materials and is the most prevalent synthetic drug manufactured in the United States. The ease of manufacturing methamphetamine and its highly addictive potential has caused the use of the drug to greatly increase throughout the Nation. The methamphetamine problem was originally concentrated in the West of the United States, but has since spread throughout almost every major metropolitan area in the country, due to the low cost, high availability, and addictive properties of this substance. There are currently no effective pharmacological treatments for ARDs and there has been limited research focused on the identification and development of medications to treat these disorders, as well as research on the health effects of chronic abuse. For these reasons, the NIDA is encouraging research in this area.
Federal Grant Title: Medications Development for the Treatment of Amphetamine and Amphetamine-Like Related Disorders (R01)
Federal Agency Name: National Institutes of Health
Grant Categories: Health Education
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-07-333
Type of Funding: Grant
CFDA Numbers: 93.279
CFDA Descriptions: Drug Abuse and Addiction Research Programs
Current Application Deadline: No deadline provided
Original Application Deadline: Multiple Receipt Dates - See Link to Full Announce
Posted Date: Mar 22, 2007
Creation Date: Mar 22, 2007
Archive Date: Dec 05, 2008
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
For profit organizations other than small businesses Independent school districts County governments Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Private institutions of higher education Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Native American tribal organizations (other than Federally recognized tribal governments) State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, An...
Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)
Research Networks for the Study of Recovery Support Services for Persons Treated with Medi...
The Rat Opioid Genome Project: Clinical Trials not Allowed (U01- Clinical Trial Not Allowe...
The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required)
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2019 FederalGrants.com